Busulfan
- Generic Name
- Busulfan
- Brand Names
- Busulfex, Myleran, Busulfan Fresenius Kabi
- Drug Type
- Small Molecule
- Chemical Formula
- C6H14O6S2
- CAS Number
- 55-98-1
- Unique Ingredient Identifier
- G1LN9045DK
- Background
Busulfan is a bifunctional alkylating agent, having a selective immunosuppressive effect on bone marrow. It is not a structural analog of the nitrogen mustards. It has been used in the palliative treatment of chronic myeloid leukemia (myeloid leukemia, chronic), but although symptomatic relief is provided, no permanent remission is brought about. According to the Fourth Annual Report on Carcinogens (NTP 85-002, 1985), busulfan is listed as a known carcinogen.
- Indication
For use in combination with cyclophosphamide as a conditioning regimen prior to allogeneic hematopoietic progenitor cell transplantation for chronic myelogenous (myeloid, myelocytic, granulocytic) leukemia (FDA has designated busulfan as an orphan drug for this use). It is also used as a component of pretransplant conditioning regimens in patients undergoing bone marrow transplantation for acute myeloid leukemia and nonmalignant diseases.
- Associated Conditions
- Chronic Myelogenous Leukemia (CML), Essential Thrombocythemia (ET), Polycythemia Vera (PV)
- Associated Therapies
- Conditioning regimens for allogeneic stem cell transplantation therapy
Donor Peripheral Stem Cell Transplant in Treating Patients With Myelodysplastic Syndrome, Acute Myeloid Leukemia, or Myeloproliferative Disorder
- Conditions
- Chronic Myeloproliferative DisordersLeukemiaMyelodysplastic SyndromesMyelodysplastic/Myeloproliferative Diseases
- First Posted Date
- 2003-01-27
- Last Posted Date
- 2010-09-16
- Lead Sponsor
- Fred Hutchinson Cancer Center
- Target Recruit Count
- 30
- Registration Number
- NCT00049634
- Locations
- 🇺🇸
Fred Hutchinson Cancer Research Center, Seattle, Washington, United States
🇺🇸Seattle Cancer Care Alliance, Seattle, Washington, United States
Combination Chemotherapy With or Without Monoclonal Antibody Therapy in Treating Patients With AML Leukemia
- Conditions
- Leukemia
- Interventions
- Biological: sargramostimProcedure: Allogeneic HCTDrug: gemtuzumab ozogamicin (GO)Procedure: Autologous HCT
- First Posted Date
- 2003-01-27
- Last Posted Date
- 2023-06-15
- Lead Sponsor
- Eastern Cooperative Oncology Group
- Target Recruit Count
- 657
- Registration Number
- NCT00049517
- Locations
- 🇺🇸
Community Medical Center, Missoula, Montana, United States
🇺🇸Penn State Cancer Institute at Milton S. Hershey Medical Center, Hershey, Pennsylvania, United States
🇺🇸Mercy and Unity Cancer Center at Mercy Hospital, Coon Rapids, Minnesota, United States
Busulfan and Cyclophosphamide Followed by Bone Marrow Transplantation in Treating Patients With Acute Myelogenous Leukemia or Myelodysplastic Syndrome
- Conditions
- Myelodysplastic SyndromesMyelodysplastic/Myeloproliferative DiseasesLeukemia
- First Posted Date
- 2003-01-27
- Last Posted Date
- 2012-06-12
- Lead Sponsor
- Northwestern University
- Registration Number
- NCT00004896
- Locations
- 🇺🇸
Robert H. Lurie Comprehensive Cancer Center at Northwestern University, Chicago, Illinois, United States
Busulfan and Etoposide Followed by Peripheral Blood Stem Cell Transplant and Low-Dose Aldesleukin in Treating Patients With Acute Myeloid Leukemia
- Conditions
- Adult Acute Myeloid Leukemia With t(16;16)(p13;q22)Recurrent Childhood Acute Myeloid LeukemiaAdult Acute Myeloid Leukemia With t(15;17)(q22;q12)Recurrent Adult Acute Myeloid LeukemiaAdult Acute Myeloid Leukemia in RemissionAdult Acute Myeloid Leukemia With 11q23 (MLL) AbnormalitiesAdult Acute Myeloid Leukemia With Del(5q)Childhood Acute Myeloid Leukemia in Remission
- Interventions
- Biological: aldesleukinProcedure: peripheral blood stem cell transplantation
- First Posted Date
- 2003-01-27
- Last Posted Date
- 2017-06-05
- Lead Sponsor
- Fred Hutchinson Cancer Center
- Target Recruit Count
- 30
- Registration Number
- NCT00003875
- Locations
- 🇺🇸
Fred Hutchinson Cancer Research Center/University of Washington Cancer Consortium, Seattle, Washington, United States
Bone Marrow Transplant in Treating Patients With Hematologic Cancers
- Conditions
- Multiple Myeloma and Malignant Plasma Cell NeoplasmsMyelodysplastic/Myeloproliferative NeoplasmsLeukemiaChronic Myeloproliferative DisordersMyelodysplastic Syndromes
- Interventions
- Radiation: Fractionated Total Body Irradiation (FTBI)
- First Posted Date
- 2003-01-27
- Last Posted Date
- 2020-12-10
- Target Recruit Count
- 125
- Registration Number
- NCT00005797
- Locations
- 🇺🇸
H. Lee Moffitt Cancer Center and Research Institute at University of South Florida, Tampa, Florida, United States
Study of Gelonin Purging of Autologous Stem Cells for Transplantation
- Conditions
- Myelodysplastic SyndromeAcute Myelogenous Leukemia
- Interventions
- First Posted Date
- 2002-08-15
- Last Posted Date
- 2018-10-31
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 3
- Registration Number
- NCT00043810
- Locations
- 🇺🇸
UT MD Anderson Cancer Center, Houston, Texas, United States
Bone Marrow Transplant From Related Donor for Patients With High Risk Hemoglobinopathies
- Conditions
- Sickle Cell AnemiaHemoglobinopathyThalassemia
- First Posted Date
- 2002-06-28
- Last Posted Date
- 2020-01-18
- Lead Sponsor
- Baylor College of Medicine
- Target Recruit Count
- 15
- Registration Number
- NCT00040469
- Locations
- 🇺🇸
Texas Children's Hospital, Houston, Texas, United States
🇺🇸The Methodist Hospital, Houston, Texas, United States
Stem Cell Transplantation After Reduced-Dose Chemotherapy for Patients With Sickle Cell Disease or Thalassemia
- Conditions
- HemoglobinopathiesAnemia, Sickle CellHemoglobin SC DiseaseThalassemiaThalassemia Major
- Interventions
- First Posted Date
- 2002-05-01
- Last Posted Date
- 2013-05-01
- Target Recruit Count
- 2
- Registration Number
- NCT00034528
- Locations
- 🇺🇸
Dana-Farber Cancer Institute/Harvard Cancer Center, Brigham and Women's Hospital and Massachusetts General Hospital, Boston, Massachusetts, United States
Cord Blood Transplantation for Sickle Cell Anemia and Thalassemia
- Conditions
- Hematologic DiseasesBeta-ThalassemiaHematopoietic Stem Cell TransplantationAnemia, Sickle Cell
- First Posted Date
- 2002-01-11
- Last Posted Date
- 2016-07-29
- Target Recruit Count
- 30
- Registration Number
- NCT00029380
- Locations
- 🇺🇸
Medical University of South Carolina, Charleston, South Carolina, United States
🇺🇸Children's Hospital, Oakland, Oakland, California, United States
🇺🇸Children's National Medical Center, Washington, District of Columbia, United States
Allogeneic Bone Marrow Transplantation in Patients With Primary Immunodeficiencies
- Conditions
- Immunologic Deficiency SyndromesChediak-Higashi SyndromeCommon Variable ImmunodeficiencyGraft Versus Host DiseaseX-Linked Lymphoproliferative SyndromeFamilial Erythrophagocytic LymphohistiocytosisHemophagocytic LymphohistiocytosisX-linked AgammaglobulinemiaWiskott-Aldrich SyndromeChronic Granulomatous Disease
- First Posted Date
- 2000-07-06
- Last Posted Date
- 2009-10-15
- Lead Sponsor
- Fairview University Medical Center
- Registration Number
- NCT00006054
- Locations
- 🇺🇸
Fairview University Medical Center, Minneapolis, Minnesota, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.